Results 11 to 20 of about 3,775 (204)

Recent Advances in Mode of Action and Biosynthesis Studies of the Clinically Used Antibiotic Fidaxomicin [PDF]

CHIMIA, 2020
The natural product antibiotic fidaxomicin is a marketed drug for the treatment of bacterial infections in the gut. Due to its promising in vitro activities against Mycobacterium tuberculosis, the development of next generation fidaxomicin analogs is of ...
Andrea Dorst, Erik Jung, Karl Gademann
doaj   +2 more sources

Fidaxomicin: A new fight against clostridium difficile-associated diarrhea

Muller Journal of Medical Sciences and Research, 2014
Clostridium difficile-associated diarrhea (CDAD) occurs commonly as a side effect of broad-spectrum antibiotics. Drugs approved for CDAD are only two of them, metronidazole and vancomycin.
Dick B. S. Brashier, Amol Khanapure, A K Sharma   +2 more
doaj   +2 more sources

Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes

Canadian Journal of Infectious Diseases and Medical Microbiology, 2016
Background. This analysis examined the efficacy of fidaxomicin versus vancomycin in 406 Canadian patients with Clostridium difficile infection (CDI), based on data from 2 randomized, clinical trials. Methods. Patients received fidaxomicin or vancomycin 1.
Christine Lee, Thomas J. Louie, Karl Weiss, Louis Valiquette, Marvin Gerson, Wendy Arnott, Sherwood L. Gorbach   +6 more
doaj   +2 more sources

Recurrent Clostridium difficile colitis in elderly: the role of fidaxomicin

Clinical Management Issues, 2014
Clostridium difficile colitis is a substantial cause of in-hospital morbidity. Since the mortality attributable may be as high as 10%, a prompt and effective treatment is advisable.
Francesco Artom, Valerio Del Bono
doaj   +3 more sources

Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infection (C. difficile-associated diarrhoea) in Ireland

Journal of Health Economics and Outcomes Research, 2015
# Background Clostridium difficile is associated with 20–30% of cases of antibiotic-associated diarrhoea. The incidence of C. difficile infection (CDI) is higher in Ireland than in other countries in Europe, and it is associated with considerable ...
Anke van Engen, Montserrat Casamayor, Fidelma Loftus, Martin Coen, Andy Garnham, Maureen Watt, Larry Lacey   +6 more
doaj   +2 more sources

Stepwise increase of fidaxomicin in an engineered heterologous host Streptomyces albus through multi-level metabolic engineering

Synthetic and Systems Biotechnology
The anti-Clostridium difficile infection (CDI) drug fidaxomicin is a natural polyketide metabolite mainly produced by Micromonosporaceae, such as Actinoplanes deccanensis, Dactylosporangium aurantiacum, and Micromonospora echinospora.
Huang Xie, Yi-Ting Su, Qing-Ting Bu, Yue-Ping Li, Qing-Wei Zhao, Yi-Ling Du, Yong-Quan Li   +6 more
doaj   +2 more sources

Total Synthesis of the Glycosylated Macrolide Antibiotic Fidaxomicin [PDF]

Organic Letters, 2015
The first enantioselective total synthesis of fidaxomicin, also known as tiacumicin B or lipiarmycin A3, is reported. This novel glycosylated macrolide antibiotic is used in the clinic for the treatment of Clostridium difficile infections. Key features of the synthesis involve a rapid and high-yielding access to the noviose, rhamnose, and orsellinic ...
Kaufmann Elias, Hattori Hiromu, Miyatake-Ondozabal Hideki, Gademann Karl   +3 more
openaire   +5 more sources

Comparison of fidaxomicin, thuricin CD, vancomycin and nisin highlights the narrow spectrum nature of thuricin CD

Gut Microbes
Vancomycin and metronidazole are commonly used treatments for Clostridioides difficile infection (CDI). However, these antibiotics have been associated with high levels of relapse in patients. Fidaxomicin is a new treatment for CDI that is described as a
L. Walsh, A. Lavelle, PM O’Connor, C. Hill, R. P. Ross   +4 more
doaj   +2 more sources

Emerging therapies for Clostridium difficile infection – focus on fidaxomicin

Infection and Drug Resistance, 2013
Fredy Chaparro-Rojas, Kathleen M MullaneDepartment of Medicine, Section of Infectious Diseases, University of Chicago, Chicago, IL, USAAbstract: The epidemiology of Clostridium difficile infections (CDI) has evolved during the last decades, with an ...
Chaparro-Rojas F, Mullane KM
doaj   +1 more source

Trends and Disparities in <i>Clostridioides difficile</i> Infection Mortality in the United States From 1999 to 2020: A Nationwide Perspective. [PDF]

Gastroenterol Res Pract
Background Clostridioides difficile infection (CDI) is one of the most prevalent infections in the United States, with rising mortality and disease severity in the early 2000s, followed by a steady decline after 2010. This study analyzes national trends in CDI mortality across different demographic and regional groups from 1999 to 2020. Methods We used
Eldesouki MH, Abusalim AR, Kloub M, Umer M, Ali MA, Shaban AY, Salem A, Almoghrabi A, Slim J, Bains Y, Dacosta T.   +10 more
europepmc   +2 more sources